Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Rhea-AI Summary
Allogene Therapeutics, Inc. will report second quarter 2023 financial results on August 2, 2023. A live audio webcast and conference call will follow the announcement.
Positive
Investors can listen to the webcast on the company's website and ask questions during the conference call.
07/26/2023 - 08:30 AM
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2023 financial results on Wednesday, August 2, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.
Listen-Only Webcast www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact: Christine.Cassiano@allogene.com
When will Allogene Therapeutics report their second quarter 2023 financial results?
Allogene Therapeutics will report their second quarter 2023 financial results on August 2, 2023.
How can investors listen to the webcast?
Investors can listen to the webcast on Allogene Therapeutics' website under the Investors tab in the News and Events section.
Can investors ask questions during the conference call?
Yes, investors can ask questions during the conference call by registering through the provided link.
Allogene Therapeutics Inc
ALLO Rankings
#5239 Ranked by Stock Gains
ALLO Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
About ALLO
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
